Fennec Pharmaceuticals (TSE:FRX) Shares Down 0.3% – Here’s Why

Fennec Pharmaceuticals Inc. (TSE:FRX)’s stock price traded down 0.3% during mid-day trading on Thursday . The stock traded as low as C$8.55 and last traded at C$8.62. 200 shares changed hands during mid-day trading, a decline of 90% from the average session volume of 2,031 shares. The stock had previously closed at C$8.65.

Wall Street Analysts Forecast Growth

Separately, Stephens upgraded Fennec Pharmaceuticals to a “strong-buy” rating in a research note on Monday, November 18th.

Fennec Pharmaceuticals Trading Up 0.7 %

The company has a debt-to-equity ratio of 1,040.68, a quick ratio of 10.17 and a current ratio of 8.02. The company has a market capitalization of C$237.48 million, a P/E ratio of 86.80 and a beta of 0.25. The company has a 50-day simple moving average of C$6.88 and a 200 day simple moving average of C$7.72.

Insider Activity at Fennec Pharmaceuticals

In other news, Senior Officer Robert Christopher Andrade bought 15,816 shares of the business’s stock in a transaction that occurred on Monday, November 18th. The stock was acquired at an average cost of C$3.43 per share, for a total transaction of C$54,248.88. Corporate insiders own 16.20% of the company’s stock.

Fennec Pharmaceuticals Company Profile

Fennec Pharmaceuticals Inc operates as a biopharmaceutical company in the United States. The company's product candidate includes PEDMARK, a formulation of sodium thiosulfate for the prevention of platinum-induced ototoxicity in pediatric cancer patients. It sells its products through regional pediatric oncology specialists and medical science liaisons.